Evren Technologies is pleased to announce the start of our IRB-approved pilot study using the Phoenix™ device to treat Post-traumatic Stress Disorder (PTSD).
The Phoenix™ Pilot Study is designed as a take-home test, following COVID social distancing and sterilization guidelines, that allows participants to use the device for a month. The primary outcome measurement for this study will be changes in the Clinician Administered PTSD Scale (CAPS-5).
“We are very excited to finally kick off our Phoenix™ Pilot Study.” Blythe Karow, President & CEO of Evren Technologies, “Having had to redesign the study for virtual protocol when the COVID outbreak hit was a bit of a delay, but now we are on track to collect valuable data validating the performance and effectiveness of our Phoenix™ prototype in locations around the US.”
To create the best PTSD treatment possible, Evren is focused on Human Centered Design throughout the development process. This pilot study will provide feedback that is crucial to our design process and allow further testing of clinical results. The focus of this study is to assess a range of parameters in both controlled laboratory experiments and extended real world at-home use.
About Evren Technologies
Evren Technologies, founded in 2018, is a privately-held medical device company headquartered in Newberry, Florida, near the University of Florida. Evren’s mission is to advance the treatment of PTSD and other psychological disorders through wearable neuromodulation products. The Company’s initial product, the Phoenix™, provides transcutaneous vagal nerve stimulation (tVNS) to treat PTSD in an effective, discreet earbud design.